바이오마커 탐색 아웃소싱 서비스 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커 유형별, 치료 분야별, 탐색 단계별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Biomarker Discovery Outsourcing Services Market Summary

The global biomarker discovery outsourcing services market size was valued at USD 17.0 billion in 2025 and is projected to grow from USD 19.9 billion in 2026 to USD 76.3 billion by 2033, at a CAGR of 21.1% from 2026 to 2033. North America dominated the market, accounting for the largest share of 43.8% in 2025. The industry is anticipated to grow owing to the increasing adoption of precision medicine, rising pharmaceutical and biotechnology research and development expenditure, growing outsourcing of biomarker discovery activities to specialized service providers, expanding application of biomarkers in oncology and other chronic diseases, and continuous advancements in genomics, proteomics, metabolomics, and multi-omics technologies.

The industry is anticipated to grow owing to the increasing adoption of precision medicine, rising pharmaceutical and biotechnology research and development expenditure, growing outsourcing of biomarker discovery activities to specialized service providers, expanding application of biomarkers in oncology and other chronic diseases, and continuous advancements in genomics, proteomics, metabolomics, and multi-omics technologies. The increasing complexity of biomarker identification and validation workflows, combined with the need for advanced analytical platforms and bioinformatics expertise, is encouraging drug developers to collaborate with specialized outsourcing partners that offer integrated discovery, validation, and data analysis capabilities across multiple therapeutic areas.

The increasing adoption of precision medicine remains a primary driver of market growth. Biomarkers play a critical role in patient stratification, target identification, treatment selection, and monitoring therapeutic response, making them an essential component of modern drug development. The growing number of targeted therapies and companion diagnostics entering clinical development is increasing the demand for advanced biomarker discovery services. The requirement for genomic sequencing, transcriptomics, proteomics, and bioinformatics analysis has further increased outsourcing among pharmaceutical and biotechnology companies seeking specialized scientific expertise and access to advanced laboratory technologies without expanding internal research infrastructure.

The growing outsourcing of biomarker discovery activities is another important factor supporting market expansion. Biomarker discovery requires access to sophisticated analytical instruments, high-quality biological samples, experienced scientific personnel, and advanced computational capabilities, which involve considerable investment and operational complexity. Therefore, pharmaceutical and biotechnology companies are increasingly partnering with contract research organizations and specialized biomarker service providers to improve development efficiency and accelerate clinical programs. This trend is further supported by continuous investments in advanced biomarker platforms. For instance, in July 2026, CellCarta launched its Global Digital Pathology and AI Consortium to integrate digital pathology, artificial intelligence, and spatial biology capabilities for biomarker discovery, patient stratification, and companion diagnostic development, further strengthening its outsourced biomarker discovery service offerings for precision medicine programs.

Market growth is moderated by the high cost of advanced omics technologies, challenges associated with biomarker validation and regulatory acceptance, and concerns related to biological sample quality and data standardization. The increasing adoption of artificial intelligence-driven biomarker discovery platforms, the expansion of multi-omics research, and the rising investment in precision oncology and personalized therapeutics are expected to create substantial opportunities for biomarker discovery outsourcing service providers over the coming years.

Thus, the biomarker discovery outsourcing services market is expected to witness steady growth as pharmaceutical and biotechnology companies continue to expand precision medicine research, increase outsourcing of specialized discovery activities, and invest in advanced biomarker-driven drug development programs. The continued evolution of multi-omics technologies, bioinformatics, and translational research capabilities is expected to further strengthen demand for integrated biomarker discovery outsourcing services.

Global Biomarker Discovery Outsourcing Services Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biomarker discovery outsourcing services market report based on biomarker type, therapeutic area, discovery phase, end-use, and region:

• Biomarker Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Predictive Biomarkers
• Prognostic Biomarkers
• Safety Biomarkers
• Surrogate Endpoints
• Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)
• Oncology
• Neurology
• Cardiology
• Autoimmune Diseases
• Other Therapeutic Area
• Discovery Phase Outlook (Revenue, USD Billion, 2021 - 2033)
• Biomarker Identification
• Biomarker Validation
• Biomarker Profiling
• Biomarker Panel Development
• Biomarker Selection
• End-use Outlook (Revenue, USD Billion, 2021 - 2033)
• Pharmaceutical Companies
• Biotechnology Companies
• Other End Use
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Biomarker Type
  • 1.2.2. Therapeutic Area
  • 1.2.3. Discovery Phase
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Biomarker Discovery Outsourcing Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Demand for Biomarkers in Drug Development
    • 3.2.1.2. Expanding R&D Investment in Biopharmaceuticals
    • 3.2.1.3. Rising Prevalence of Chronic and Infectious Diseases
    • 3.2.1.4. Increasing focus on personalized medicine and targeted therapies
    • 3.2.1.5. Advancements in Omics Technologies
    • 3.2.1.6. Increasing Role of CROs and CDMOs Owing to Cost and Time Efficiency
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited Reproducibility & Validation Challenges
    • 3.2.2.2. High Cost of Biomarker Discovery & Validation
    • 3.2.2.3. Data Privacy & Security Concerns
• 3.3. Technology Landscape
  • 3.3.1. Integration of AI and Big Data in Biomarker Research
  • 3.3.2. Omics Technologies
  • 3.3.3. Role of Bioinformatics & Cloud Computing
• 3.4. Pricing Model Analysis
• 3.5. Value Chain Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Force Analysis
  • 3.6.2. PESTEL Analysis

Chapter 4. Biomarker Discovery Outsourcing Services Market: Biomarker Type Estimates & Trend Analysis

• 4.1. Biomarker Discovery Outsourcing Services Market, By Biomarker Type: Segment Dashboard
• 4.2. Biomarker Discovery Outsourcing Services Market, By Biomarker Type: Movement Analysis
• 4.3. Biomarker Discovery Outsourcing Services Market Estimates & Forecasts, By Biomarker Type, 2021 - 2033 (USD Billion)
• 4.4. Predictive Biomarkers
  • 4.4.1. Predictive Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.5. Prognostic Biomarkers
  • 4.5.1. Prognostic Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.6. Safety Biomarkers
  • 4.6.1. Safety Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.7. Surrogate Endpoints
  • 4.7.1. Surrogate Endpoints Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Biomarker Discovery Outsourcing Services Market: Therapeutic Area Estimates & Trend Analysis

• 5.1. Biomarker Discovery Outsourcing Services Market, By Therapeutic Area: Segment Dashboard
• 5.2. Biomarker Discovery Outsourcing Services Market, By Therapeutic Area: Movement Analysis
• 5.3. Biomarker Discovery Outsourcing Services Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Billion)
• 5.4. Oncology
  • 5.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.5. Neurology
  • 5.5.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.6. Cardiology
  • 5.6.1. Cardiology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.7. Autoimmune Diseases
  • 5.7.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.8. Other Therapeutic Area
  • 5.8.1. Other Therapeutic Area Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Biomarker Discovery Outsourcing Services Market: Discovery Phase Estimates & Trend Analysis

• 6.1. Biomarker Discovery Outsourcing Services Market, By Discovery Phase: Segment Dashboard
• 6.2. Biomarker Discovery Outsourcing Services Market, By Discovery Phase: Movement Analysis
• 6.3. Biomarker Discovery Outsourcing Services Market Estimates & Forecasts, By Discovery Phase, 2021 - 2033 (USD Billion)
• 6.4. Biomarker Identification
  • 6.4.1. Biomarker Identification Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.5. Biomarker Validation
  • 6.5.1. Biomarker Validation Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.6. Biomarker Profiling
  • 6.6.1. Biomarker Profiling Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.7. Biomarker Panel Development
  • 6.7.1. Biomarker Panel Development Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.8. Biomarker Selection
  • 6.8.1. Biomarker Selection Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Biomarker Discovery Outsourcing Services Market: End Use Estimates & Trend Analysis

• 7.1. Biomarker Discovery Outsourcing Services Market, By End Use: Segment Dashboard
• 7.2. Biomarker Discovery Outsourcing Services Market, By End Use: Movement Analysis
• 7.3. Biomarker Discovery Outsourcing Services Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Billion)
• 7.4. Pharmaceutical Companies
  • 7.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.5. Biotechnology Companies
  • 7.5.1. Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Biomarker Discovery Outsourcing Services Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Laboratory Corporation of America Holdings (LabCorp)
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Charles River Laboratories
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Eurofins Scientific
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Celerion
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. ICON plc.
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Parexel International (MA) Corporation
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Proteome Sciences
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. GHO Capital
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Thermo Fisher Scientific Inc.
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Evotec
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives